Tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases; an open, multicenter, randomized non-inferiority phase 3-trial (PI: Ingvil Mjaaland)
Inclusion Criteria:
- Primary unifocal or multifocal invasive breast cancer T1-T2.
- Clinically N0.
- Macrometastasis (≥2mm) in 1-2 lymph nodes at sentinel node biopsy.
- Oral and written consent.
- Age ≥ 18 years.
- All resection margins are tumor free (no tumor on ink).
- Primary tumor ER-positive, HER2-negative.
Exclusion Criteria:
- Regional or distant metastases outside the ipsilateral axilla.
- Previous RT towards the planned target area, i.e. the ipsilateral chest/lymph nodes.
- Neoadjuvant systemic therapy.
- Axillary lymph node dissection or other previous axillary surgery on the affected side.
- Prior history of invasive breast cancer.
- Pregnancy.
- Bilateral invasive breast cancer.
- Contraindication for radiotherapy or systemic treatment.
- Inability to absorb or understand the contents of the informed consent form; for example, through disability, inadequate language skills or dementia.
- Other invasive cancer within 5 years prior to breast cancer diagnosis